Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism

Hospital Avicenne

Status: Completed

Conditions: Dystonia; Parkinson Disease; Atypical Parkinsonism

Study type: Observational

Funder types: Other

Identifiers

NCT04948684

CLEA-2021-167

Details and patient eligibility

About

Dystonia is a disabling symptom affecting both patients with idiopathic Parkinson's disease (PD) and atypical parkinsonism (AP).

Botulinum toxinum (BoNT), by blocking muscle contraction, is a possible treatment for focal dystonia.

The benefit of BoNT treatment has been proven in some focal dystonia associated with PD or AP.

The investigators aim to give an overview of the efficacy of BoNT in a variety of focal dystonia in a large cohort of parkinsonian patients.

Enrollment: 63 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed Parkinson's disease or Atypical Parkinsonism
• Age > 18 years
• Reported dystonia
• At least 1 injection with Botulinum toxin realized

Exclusion criteria

• Refusal to participate in the study

Trial design

63 participants in 2 patient groups

Patients with dystonia secondary to atypical Parkinsonism or Parkinson's disease

Description:

Patients with dystonia secondary to idiopathic Parkinson's disease or atypical parkinsonism and treated with BoNT

Patients with atypical Parkinsonism or Parkinson's disease and no dystonia

Description:

Patients with idiopathic Parkinson's disease or atypical parkinsonism and without reported dystonia